![]() Acadia said in its 2022 earnings call on Monday that it is “eagerly awaiting” communication from the U.S. That drug, renamed trofinetide, was eventually licensed to the American company Acadia Pharmaceuticals and now stands on the cusp of approval, though for the genetic neurodevelopmental condition Rett syndrome, not traumatic brain injury. ![]() “Are you seeing improvements? Because there’s no point in taking a drug if you’re not.” David Lieberman It was the data they had been looking for. ![]() ![]() And then one day in 2002 during a weekly lab meeting, the biologists on the Neuren team presented promising in-vitro data for NNZ-2566, showing it possessed clear neuroprotective effects. But Brimble slid it to the back burner and let it simmer while she and her colleagues explored other leads. It was nearly enough to make them give up. The peptide was intriguing, but it needed to be synthesized at just the right temperature and on an exact timeline - and even then the reaction was capricious. She and three chemists from her lab were focused on analogs of a natural peptide of insulin-like growth factor 1 (IGF-1), chasing one in particular they called NNZ-2566. The country was not exactly known as a hotbed of drug development, but Brimble was an optimist, a dedicated chemist and maybe even a bit of a dreamer - she was working to create new drugs for traumatic brain injuries at a spinout company called Neuren Pharmaceuticals. ![]() Margaret Brimble was a new professor in 1999 at the University of Auckland in New Zealand. ![]()
0 Comments
Leave a Reply. |